824PRadium-223 (Ra-223) therapy after abiraterone (Abi): Analysis of symptomatic skeletal events (SSEs) in an international early access program (iEAP) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). (23rd October 2018) - Miller, K; Heinrich, D; O'Sullivan, J M; Carles, J; Wirth, M; Nilsson, S; Huang, L; Kalinovsky, J; Heidenreich, A; Saad, F